HCV genotype 1b Con1 subgenomic replicon cell lines Huh-luc/neo-ET containing a luciferase reporter, Huh 9-13, and HCV genotype 1b plasmid pFK-I389/NS3-3 were provided by Dr. Ralf Bartenschlager from The University of Heidelberg 1, 2 . HCV genotype 2a genomic RNA JFH1 clone was a gift of Dr. Takaji Wakita (Tokyo Metropolitan Institute of Neuroscience, Tokyo Metropolitan Organization for Medical Research, Japan). Huh luc/neo-ET and Huh 9-13 cells were maintained in DMEM medium supplied with 10% FBS, 1 mM nonessential amino acids (Invitrogen), and 250 µg/ml G418 (Gibco).
GCTGTTGTCCAGTCTGATATGcgaaCATATCAGACTGGACAACAGC-3') (SENSE-loop-ANTISENSE), Hsc70 shRNA-2 (5'-GCCCAAGGTCCAAGTAGAATAcgaaTATTCTACTTGGACCTTGGGC-3') (SENSE-loop-ANTISENSE).
The HCV pFKI389 lucubineo NS3-3' plasmid was a generous gift from Dr. Ralf
Bartenschlager at the University of Heidelberg 1 .
The Hsc70 NBD (residues 1-385) plasmid was constructed by inserting a stop codon after position 1155 in the Hsc70 FL pET28a plasmid using the QuikChange® XL sitedirected mutagenesis kit (Stratagene). The D206S mutation in the Hsc70 gene, rHsc70-1, rHsc70-2, and the D318N mutation in the NS5B gene were introduced using the QuikChange® XL site-directed mutagenesis kit. The ER-Hsc70 plasmid was constructed by inserting the ER localization signal peptide (MSFVSLLLVGILFWATEQLTKCEVFQ) into the N-terminus of HA-Hsc70 plasmid. Primers used for mutagenesis are shown in Table S1 . Poly A was cloned from synthetic poly A into a pGL4 vector. To generate the HCV pFKI389 lucubineo NS3-3' plasmid without the poly U/UC motif at the 3' NTR, we cloned the plasmid without the poly U/UC motif by adding a Sca I site to the end of the NS5B coding region, and ligated the linear DNA by the new Sca I site and the existing Sca I site after the poly U/UC motif.
Generation of HLN-cure cells
Highly permissive HLN-cure cells were derived by through interferon treatment similar to the derivation of Huh 7.5 cells described previously 3 . Briefly, Huh-luc/neo-ET cells were passaged twice in the absence of G418 and then cocultured with 100 IU/ml of recombinant human IFNα-2a (Pestka Biomedical Laboratories) for 3 days. On the fourth day, cells were passaged and cultured for 24 hours before re-introduction of IFNα-2a.
Cells were then passaged for eight times in the presence of IFNα-2a and rested at every fourth passage. The elimination of HCV RNA was monitored by Real-Time PCR. HLNcure cells, verified to be free of HCV RNA, were propagated and expanded without IFNα-2a. Electroporation was conducted using HLN-cure cells that were passaged fewer than 20 times from the cryopreserved HLN-cure stocks.
Transfection of plasmids
All plasmids were cleared of endotoxins using the EndoGO kit (MirusBio, Madison, WI) prior to transfection. Transfection was performed with TransIT-LT1 transfection reagent (MirusBio) for Huh-luc/neo-ET cells according to the manufacturers' instructions. HCV mRNA was transfected into Huh 7.5 cells by electroporation according to the protocol described previously 4 .
Expression and purification of recombinant Hsp70, full length and different domains of Hsc70
Primers for the construction of expression vectors of for His-tagged Hsp70, full-length Hsc70, and different Hsc70 domains are shown in Table S1 . Recombinant proteins were overproduced in E.coli BL21 (DE3) pLysS cells (Promega, Madison, WI) at 22°C for 4 hours, and purified by Ni 2+ -NTA agarose (Qiagen, Valencia, CA).
Determination of anti-HCV activity by luciferase reporter assay
Firefly-luciferase reporter activity was used to monitor the replication of HCV replicons in Huh-luc/neo-ET cells free from G418
5
. Luciferase activity was measured with a luciferase assay kit (Promega) on Tecan FARCyte Luminometer (GE Healthcare)
according to the manufacturer's instruction.
RNA isolation and Real-Time PCR
Total RNA was isolated using the High Pure RNA isolation kit (Roche, Mannheim, Germany). cDNA was synthesized from total RNA using random primers according to the protocol of the iScript TM cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA), and expression levels of specific genes were quantified by Real-Time PCR with genespecific primers (Table S5 ) using the SsoFast TM EvaGreen supermix (Bio-Rad Laboratories). Absolute copy number of HCV RNA was determined with the standard curve generated using the linearized pFK-I389/NS3-3′ plasmid bearing the HCV genome and 18S rRNA was included as a control.
In vitro transcription assay
HCV subgenomic replicon encoding plasmid pFK I389 lucubineo NS 3-3' was linearized by ScaI. Different fragments of the 3' NTR region from HCV RNA were cloned into a TA-PCRII vector (Invitrogen) with a T7 promoter. Primers used for cloning are provided in Table S1 . The linearized plasmids were used as the template for in vitro transcription.
Uncapped and capped HCV replicon mRNAs were generated using the MEGAscript kit containing T7 RNA polymerase (Ambion, Austin, TX). The in vitro transcribed mRNAs were purified using the MEGAclear kit (Ambion). The integrity of the in vitro transcribed mRNAs was confirmed using the Agilent 2100 Bioanalyzer (Foster City, CA). The purified mRNAs were used for in vitro translation experiments, or in vitro RNA binding assays, or ATPase hydrolysis assays.
Antibodies
The following antibodies were used: rabbit and mouse IgG, anti-Alix (2171, Cell International). All antibodies were used at a 1:2,000 dilution for Western blot analysis.
Optiprep iodixanol continuous density gradient
Optiprep iodixanol density media was purchased from Sigma-Aldrich. Continuous density gradients were performed as described 6 . Briefly, 10 7 Huh-luc/neo-ET cells were Continuous 5-30% optiprep iodixanol gradients were prepared in 78 mM KCl, 4 mM MgCl2, 8.4 mM CaCl2, 10 mM EDTA, and 50 mM Hepes-NaOH at pH 7.0 using a gradient mixer and stored at 4 °C. Post-nuclear supernatant was loaded on top of the gradient media, and centrifuged at 36,000 rpm at 4°C using a SW 41Ti Beckman Coulter rotor for 80 minutes. Each sample was collected and divided into 12 fractions by an Autodensi-Flow Gradient Fractionator.
Preparation of HCV crude replication complexes (CRCs)
Preparation of CRCs was adapted from a previous protocol with modification 7 . All reagents were RNase-free. Ten million Huh 9-13 or Huh luc/neo-ET cells were incubated with 1 ml ice-cold hypotonic buffer containing 0.25 M sucrose, 4 mM MgCl2, 8.4 mM CaCl2, 10 mM EDTA, 50 mM Hepes-NaOH at pH 7.0 with complete protease inhibitor, 4% ribonucleoside vanadyl, and 400 U RNase Out. After sitting on ice for 30 minutes, cells were lysed by 30 passages through a 20-gauge needle, and centrifuged three times at 1,000 g for 5 minutes at 4°C to remove cellular debris and nuclei. The supernatant was centrifuged in a Beckman TL-100 ulatracentrifuge with TLS-55 rotor at 15,000 g for 20 minutes at 4 C, and the resulting pellet was used as CRCs.
Immunoprecipitation of Hsc70-associated protein and mRNA complexes (RNA-IP)
RNA-IP was performed as described by Keene et al 
Characterization of ATP hydrolysis activity of Hsc70
Characterization of the ATP hydrolysis activity of Hsc70 was described previously and HA-NS4B with Hsc70 were examined by immunoprecipitation as described in Figure   4A . (B) Hsc70-associated complex was immunoprecipitated with Hsc70 antibody. The levels of surivin and β-actin RNA were examined by real-time PCR as in Figure 5B .
(C)
The Hsc70-associated complex was treated with 100 μg/ml RNase for 2 hours before subject to SDS PAGE and Western blot analysis of NS5A and NS5B levels. 
